All News
Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation
MedPage Today
Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.
Read Article
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.
Read Article
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush RheumNow ( View Tweet)
Putting IL17i into ‘focus’ for SpA-associated uveitis
The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU
Dr. John Cush RheumNow ( View Tweet)
Difficult to Treat Axial Spondyloarthritis
Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF
Links:
Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA
Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona
https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm
Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Xeligekimab in AS
Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain
https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time?
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay decreased over time
🔹️Same trends across world regions & across Human Development Index categories
POS0908 #EULAR2025
@RheumNow https://t.co/Y9gxQDV9KJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Impact of TNFi on efficacy of Vunakizumab in AS.
-Post hoc analysis of Vunakizumab
(humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts.
-440 total pts, 163 had prior TNFi exposure
- At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l
Adela Castro AdelaCastro222 ( View Tweet)
Sacroiliac joint involvement in #Psoriatic_arthritis
🔹️681 patients
🔹️Age 45
🔹️31% MRI-positive sacroiliitis
🔹️29% radiographic sacroiliitis
🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis
POS0297
#EULAR2025
@RheumNow https://t.co/gKANc6mNZB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Data from COAST-V study (post hoc)
🔹️Ixekizumab in #axSpA
🔹️Efficacy stratified by CRP level
🔹️Better treatment response in the elevated compared to the normal CRP group
OP0699
#EULAR2025
@RheumNow https://t.co/1mVoly3Gws
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?
🔹️245 pts
🔹️CRP recorded for past 5y
🔹️sustained high CRP in 40%
🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis
POS0714
#EULAR2025
@RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢!
German national Bechterew-App RCT of
App based intervention AXIA, control group was standard of care
200pts 12wks
ASAS20 response 51% vs. 9%
ASAS40 response rate 23% vs. 3%
BASDAI:
Aurelie Najm AurelieRheumo ( View Tweet)
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
✅ Only 13% linked SLE control to CVD risk
🚫 0% picked correct BP/statin use in RA/AS/PsA
Barriers? Time, knowledge, and local guideline gaps.
POS0410-HPR @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though?
This app (Axia) in axSpA was basically as good as a biologic.
Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that
#EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
Links:
David Liew drdavidliew ( View Tweet)
Suppression of inflammation fire 🔥 in #axSpA
may prevent subclinical atherosclerosis progression ❤️
🔺️90 patients
🔺️74% achieved LDA at 12 mo
🔺️Carotid plaque progression was higher in non-LDA group
POS1311
#EULAR2015
@RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RA is worst with temperature rising/ climate change.
However SpA has the opposite effect!
Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD
Bella Mehta bella_mehta ( View Tweet)
